Actionable news
0
All posts from Actionable news
Actionable news in PRGO: PERRIGO COMPANY PLC,

Prospectuses and communications, business combinations

BGCOLOR="WHITE">

Pursuant to Rule 425 under the Securities Act of 1933

Subject Company:

Perrigo Company plc

Commission File No. 001-36353

Mylan Schedules Third Quarter 2015 Financial Results Conference Call

and Live Webcast

Mylan Also to Schedule Separate Webcast to Discuss the Compelling Value Creation

Inherent in its Offer to Acquire Perrigo

HERTFORDSHIRE, England and PITTSBURGH, Oct. 5, 2015 - Mylan N.V. (Nasdaq: MYL), a leading global pharmaceutical company, today announced that it will host a conference call and live webcast on Friday, Oct. 30, 2015, at 10 a.m. ET, to review the companys financial results for the third quarter ended Sept. 30, 2015. Mylan will release its financial results on Friday, Oct. 30, 2015 before the market opens.

Mylan also intends to provide an overview during the earnings call of its 60-day plan for Perrigo Company plc (NYSE:PRGO; TASE) should Mylan receive greater than 50% of the tender and take control of Perrigo.

Mylan also announced that it intends to provide Perrigo shareholders with a comprehensive presentation during the week of Oct. 12 outlining the clear and compelling value creation inherent for them in Mylans offer to acquire Perrigo.

Mylans Executive Chairman Robert J. Coury commented, Even after the recent market sell off and the healthcare sector revaluation, we believe that a significant portion of Perrigo shareholders have recognized that Mylans firm, fully financed compelling offer represents a generous multiple of Perrigos EBITDA, and is one of the highest ever paid for this type of business. It is even more attractive when considering the significant portion of Perrigos earnings are generated from a single, non-core royalty asset, Tysabri ® , which is expected to have little to no growth. Several months of a public process clearly have proven that there does not seem to be any other firm third party interest in acquiring Perrigo at such a value.

We very much look forward to a dialogue with Perrigo shareholders in the coming weeks to provide them with additional details regarding the value of our compelling offer, and we remain fully confident that we will receive their support.

Under the terms of Mylans offer, Perrigo shareholders will receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share. On Sept. 14, 2015 Mylan officially commenced its formal offer to acquire all outstanding ordinary shares of Perrigo.

The offer is being made in accordance with Mylans announcement (dated April 24, 2015 and amended on April 29, 2015 and on Aug. 13, 2015) pursuant to Rule 2.5 of Irish Takeover Rules that set forth Mylans legally binding commitment to commence an offer for the entire issued and to be issued share capital of Perrigo. The offer and withdrawal rights are scheduled to expire at 1 p.m. (Irish time)/8 a.m. (New York City time) on Nov. 13, 2015, unless the offer is extended with the consent of the Irish Takeover Panel. The acceptance condition for the offer requires greater than 50% of Perrigo ordinary shares to have been tendered into the offer.

A copy of the Offer to Exchange/Prospectus (being the offer document for the purposes of the Irish Takeover Rules) and other related materials have been mailed to Perrigo shareholders and the Offer to Exchange/Prospectus is available at perrigotransaction.mylan.com.

The dial-in number to access the earnings call is 800.514.4861 or 678.809.2405 for international callers. To access the live webcast, please log on to Mylans website, mylan.com, at least 15 minutes before the event is scheduled to begin to register and download or install any necessary software. A replay of the webcast will be available at mylan.com/investors, for a limited time.

ABOUT MYLAN

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do whats right, not whats easy; and impact the future through passionate global leadership. We offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. Our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.

FORWARD-LOOKING STATEMENTS

This communication contains forward-looking statements. Such forward-looking statements may include, without limitation, statements about the proposed acquisition of Perrigo Company plc (Perrigo) by Mylan N.V. (Mylan) (the Perrigo Proposal), Mylans acquisition (the EPD Transaction) of Mylan Inc. and Abbott Laboratories non-U.S. developed markets specialty and branded generics business (the EPD Business), the benefits and synergies of the Perrigo Proposal or EPD Transaction, future opportunities for Mylan, Perrigo, or the combined company and products, and any other statements regarding Mylans, Perrigos, or the combined companys future operations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations and targets for future periods. These may often be identified by the use of words such as will, may, could, should, would, project, believe, anticipate, expect, plan, estimate, forecast, potential, intend, continue...


More